|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cisbio Bioassays Marks Next Step in Development of Tag-lite(TM) GPCR Investigation Platform
9/30/2009 1:42:43 PM
Bagnols-sur-Cèze, France – September 30, 2009 – Cisbio Bioassays (www.htrf.com), a member of IBA
group and global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services
used in assay development and drug screening, today announced that it has extended its Tag-lite™ cell surface
receptor platform with the introduction of a comprehensive catalogue of ligands and plasmids. The new
catalogue marks the next step in the company’s development of a complete array of tools for G-Protein Coupled
Receptor (GPCR) investigation and, more specifically, of Tag-lite, its homogeneous and non-radioactive
alternative for the study of cell surface receptor dimerization and ligand binding.
The catalogue comprises an initial selection of peptidic and non-peptidic fluorescent ligands and SNAP-GPCR
plasmids. These are used to develop a homogeneous and non-radioactive partner for investigating and for
screening receptor activity. Receptor families that have been characterized using the Tag-lite platform include
chemokine, dopamine, melanocortin, opioid, tachykinin, vasoactive intestinal peptide and vasopressin, among
others. Cisbio Bioassays will also provide specific ligand development services upon request.
“Tag-lite has been developed for cell receptor ligand binding studies and emerging applications such as receptor
dimerization, and this new catalogue represents only the beginning of our expansion of this platform,” said
François Degorce, head of marketing at Cisbio Bioassays. “We are consistently putting together new ideas for
how this platform can improve drug discovery, and are already on the cusp of launching new ligands, cells and
applications with new receptors.”
Launched earlier this year and recipient of the 2009 Frost & Sullivan North America Technology Innovation of
the Year Award, Tag-lite is a cell surface receptor platform combining HTRF and SNAP™-tag technologies.
Streamlined for highly selective ligand binding and receptor dimerization assays, this rapid, non-radioactive
platform meets needs to investigate GPCR network signaling, while preserving the functionality of the receptor
and the intracellular signaling pathway. GPCRs, with their complex signaling network pathways, are the most
important target class studied in the drug discovery industry today and are of particular relevance to therapeutic
areas such as obesity and CNS disorders. Cisbio Bioassays’ tools and technologies, including Tag-lite, Cellul’erk
for phosphorylated-ERK1/2 investigation, IP-One and cAMP second messenger assays, enable researchers to
investigate GPCRs from an increasing number of mechanistic and functional angles, both inside and outside the
cell.
About Cisbio Bioassays
Cisbio Bioassays is a global developer of products and technologies used in in vitro diagnostics and assay development for
drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary
technology, HTRF®, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the
pharmaceutical industry for the high throughput screening stage of drug development. In addition, Cisbio Bioassays
produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as
contract research organizations (CROs). Headquartered in Bagnols-sur-Cèze, France, with facilities in Bedford, MA, U.S.A.
and a network of distributors worldwide, Cisbio Bioassays is a member of the Belgium-based IBA group. Founded in 1986 in
Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art
equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus
gained to provide electron accelerators for industrial sterilization and ionization. Listed on the pan-European stock exchange
Euronext, IBA is included in the BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Please visit www.htrf.com
and www.iba-worldwide.com for more information about Cisbio Bioassays and IBA.
|
|
|
|
|
|
|
|